Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Ph-негативные миелопролиферативные заболевания

Список литературы

  1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82. doi: 10.1200/JCO.2010.29.8711.
  2. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных заболеваний Клиническая онкогематология. 2016; 9 (3): 314-325.
  3. R.C.Skoda, A. Duek, J. Grisouard. Pathogenesis of myeloproliferative neoplasms. Experimental Hematology. 2015; 43(8): 599-608 https://doi.org/10.1016/j.exphem.2015.06.007
  4. Schischlik F., Kralovics R. Mutations in myeloproliferative neoplasms - their significance and clinical use. Expert Rev Hematol. 2017;10(11):961-973. doi: 10.1080/17474086.2017.1380515. Epub 2017 Sep 25.
  5. W. Vainchenker, Franc¸ois Delhommeau, Stefan N. Constantinescu, Olivier A. Bernard. New mutations and pathogenesis of myeloproliferative neoplasms. BLOOD, 2011. 118(7):1723-1735; doi: https://doi.org/10.1182/blood-2011-02-292102
  6. H. C. Hasselbalch, M. E. Bjørn. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476.
  7. Mehta J., Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.
  8. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. Монография. С-Пет. 2016; 298
  9. WHO Classification of tumours of lymphoid and hematopoietic tissues. Lyon: IARC; 2017;585.
  10. NCCN Clinical Practice Guidelines in Oncology Myeloproliferative neoplasms version I.2020-May 21.2020
  11. R. M. Emanuel, A. C. Dueck, H. L. Geyer, J.-J. Kiladjian, S. Slot, S. Zweegman,P. A.W. te Boekhorst, S. Commandeur, H. C. Schouten, F. Sackmann, A. K. Fuentes, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. J Clin Oncol. 2012; 30(33): 4098-4103. doi: 10.1200/JCO.2012.42.3863
  12. Vannucchi A. M., T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. Kröger, J. Thiele, Buske C. Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms: ESMO Clinical Practice Guidelines. Ann Oncol. 2015; 26 (5): 85-99.
  13. Agarwal M. B., Malhotra H., Chakrabarti P., Varma N., Mathews V., Bhattacharyya J., T. Seth, K. Gayathri, H. Menon, P. G. Subramanian, A. Sharma, M. Bhattacharyya, J. Mehta, A. K. Vaid, S. Shah, S. Aggarwal, P. K. Gogoi, U. Agarwal, Varma. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol. 2015; 36(1): 3-16. doi: 10.4103/0971-5851.151770
  14. Ионова Т.И., Виноградова О.Ю., Ефремова Е.В. и др. Разработка и результаты апробации русской версии опросника MPN10 для оценки симптомов у пациентов с миелопролиферативными новообразованиями с учетом международных рекомендаций. Клиническая онкогематология. 2020;13(2):176-84. DOI: 10.21320/2500-2139-2020-13-2-176-184
  15. Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016;146(4):408-22. doi: 10.1093/ajcp/aqw131.
  16. Шихбабаева Д.И. Значение клинических и молекулярно-генетических факторов в стратификации рисков у больных истинной полицитемией. 2017. Канд.диссертация. 113
  17. Hoffman R. et al. Hematology: Basic Principles and Practice E-Book 7th edition 2017 https://books.google.de/books?isbn=0323509711
  18. Toros A. B., Gokcay S., Cetin G., Ar M. C., Karagoz Y., Kesici B. Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed. ISRN Hematol.Volume 2013, Article ID 673781, 5 pages http://dx.doi.org/10.1155/2013/673781
  19. Pieri L., Guglielmelli P., Vannucchi A. M. Chronic Myeloproliferative Neoplasms: a Collaborative Approach. Mediterr J Hematol Infect Dis. 2010; 2(2): e2010017. Published online 2010 Jun 21. doi: 10.4084/MJHID.2010.017
  20. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232
  21. Michiels J. J., Berneman Z., Schroyens W. et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006; 32:589-604.
  22. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81. doi: 10.1038/leu.2013.163.
  23. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Practice-relevant revision of IPSET- thrombosis based on 1019 patients with WHO-definedessential thrombocythemia. Blood Cancer J. 2015;5:e369. doi: 10.1038/bcj.2015.94.
  24. Cervantes F. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009. 113(13). 2895-901.
  25. Passamonti F., Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia inprimary myelofibrosis. Blood. 2010;116(15):2857-8. doi: 10.1182/blood-2010-06-293415.
  26. Gangat N., Caramazza D., Vaidya R. et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology. 2011. 29(4). 392-7.
  27. R. Marchioli, G. Finazzi, G. Specchia, A. Masciulli, M. Rosaria Mennitto, T. Barbui The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients With Polycythemia Vera. Thrombosis. 2011;2011:794240. doi: 10.1155/2011/794240. Epub 2011 May 17.
  28. A. Tefferi, T. Barbui. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2017; 92 (1) 94-108 https://doi.org/10.1002/ajh.24607
  29. A. Tefferi, T. Barbui. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2019; 94 (1) 133-143 https://doi.org/10.1002/ajh.25303.
  30. Меликян А.Л. ЭРИТРОЦИТАФЕРЕЗ ПРИ ЛЕЧЕНИИ ИСТИННОЙ ПОЛИЦИТЕМИИ. Диссертация на соискание ученой степени кандидата медицинских наук / Гематологический научный центр. Москва, 1984, 1-96
  31. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016). Гематология и трансфузиология. 2017; 1:25-60
  32. Author links open overlay panelTs'ai-fanYuM.D(Research Professor of Medicine)1NealWeinrebM.D.(Associate in Medicine)1RuthWittmanB.A.(Research Assistant)1Louis R.WassermanM.D. Secondary gout associated with chronic myeloproliferative disorders. Seminars in Arthritis and Rheumatism Volume 5, Issue 3, February 1976, Pages 247-256
  33. Инструкция по медицинскому применению препарата. Jakavi (ruxolitinib): SmPC. https://www.ema.europa.eu/en/documents/product-information/jakavi-epar-product-information_en.pdf
  34. Jean-Jacques Kiladjian , Pierre Zachee , Masayuki Hino, Fabrizio Pane, Tamas Masszi , Claire N Harrison, et al. Long-term Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-year Follow Up of a Phase 3 Study. Lancet Haematol. 2020;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23.
  35. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European Leukemia Net consensus conference. Blood 2009;113(20):4829-4833.
  36. Alvarez-Larran A., Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116:1205-10.
  37. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(12):1551-1560. doi: 10.1002/ajh.25230.
  38. Shantzer L, Berger K, Pu JJ. Primary myelofibrosis and its targeted therapy. Ann Hematol. 2017;96(4):531-535. doi: 10.1007/s00277-016-2785-9.
  39. Gowin K, Ballen K, Ahn K, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973. doi:10.1182/bloodadvances.2019001084
  40. McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104(4):659-668. doi: 10.3324/haematol.2018.206151.
  41. Nicolaus Kröger, Toni Giorgino , Bart L Scott, Markus Ditschkowski, Haefaa Alchalby , Francisco Cervantes, et al. Impact of Allogeneic Stem Cell Transplantation on Survival of Patients Less Than 65 Years of Age With Primary Myelofibrosis. Blood 2015;125(21):3347-50; doi: 10.1182/blood-2014-10-608315. Epub 2015 Mar 17.
  42. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015;29:2126-33.
  43. Primary myelofibrosis: 2021 update on diagnosis,risk-stratification and management Ayalew TefferiAm J Hematol. 2021;96:145-162. wileyonlinelibrary.com/journal/ajh
  44. Maria Vladimirovna Barabanshikova , Igor Nikolaevich Zubarovsky ,Vjacheslav Mikhailovich Savrasov , Andrey Jurjevich Korolkov ,Vadim Valentinovich Baykov , Anna Vjacheslavovna Botina ,Julia Jurjevna Vlasova , Ivan Sergeevich Moiseev ,Elena Igorevna Darskaya , Elena Vladislavovna Morozova ,Boris Vladimirovich Afanasyev Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):140-145
  45. Bossard JB, Beuscart JB, Robin M. et al; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), the France-Intergroupe des Syndromes Myéloprolifératifs (FIM) and the Agencede la BioMédecine (ABM)Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: a French nationwide study. Am J Hematol. 2020;96(1):80-88. https://doi.org/10.1002/ajh.26034.
  46. Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, et al. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(6):958-964. doi: 10.1016/j.bbmt.2017.03.002.
  47. Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol 2018;101:305-17.
  48. Shanavas M, Popat U, Michaelis LC, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant 2016;22:432-40.
  49. Salit RB, Scott BL, Stevens EA, Baker KK, Gooley TA, Deeg HJ. Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transplant 2020;55:70-6.
  50. Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant 2016;51:617-8.
  51. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review Mario Tiribelli . Francesca Palandri, Emanuela Sant’Antonio, Massimo Breccia, Massimiliano Bonifa Bone Marrow Transplantation (2020) 55:708-716https://doi.org/10.1038/s41409-019-0683-1
  52. Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103(3):438-446. doi: 10.3324/haematol.2017.181297.
  53. Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol. 2017;98(4):407-414. doi: 10.1111/ejh.12846.
  54. Cervantes F., Alvarez-Larrán A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005;129(6):771-5.
  55. Al-Ali H. K., Griesshammer M., le Coutre P., Waller C. F., Liberati A. M., Schafhausen P., Tavares R., Giraldo P., Foltz L., Raanani P., Gupta V., Tannir B., Ronco J. P., Ghosh J., Martino B., Vannucchi A. M. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065-1073.
  56. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.
  57. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein M.N. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95(7):2226-33.
  58. Меликян А. Л., Колосова Л. Ю., Соколова М. А., Ковригина А. М., Силаев М. А., Гилязитдинова Е. А., Гемджян Э. Г., Карагюлян С. Р. Роль спленэктомии при лечении больных миелофиброзом. Тер.архив. 2013.8, 69-76.
  59. Nicolosi M, Mudireddy M, Patnaik MM, Gangat N, Pardanani A, Tefferi A. A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. Am J Hematol. 2018;93(4):E103-E107. doi: 10.1002/ajh.25037.
  60. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P. Iron toxicity - Its effect on the bone marrow. Blood Rev. 2018;32(6):473-479. doi: 10.1016/j.blre.2018.04.004.
  61. Quintás-Cardama A1, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27(28):4760-6. doi: 10.1200/JCO.2009.22.6548.
  62. Mesa RA1, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116(22):4436-8. doi: 10.1182/blood-2010-05-287417.
  63. A. Tefferi, F. Cervantes, R. Mesa, F. Passamonti, S. Verstovsek, A.M. Vannucchi, J. Gotlib, B. Dupriez, Animesh Pardanani, C. Harrison, R. Hoffman, H. Gisslinger, N. Kröger, J. Thiele, T. Barbui, and G Barosi Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013 122:1395-1398; doi: https://doi.org/10.1182/blood-2013-03-488098
  64. Scherber RM, Mesa RA. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018;2018(1):118-126. doi: 10.1182/asheducation-2018.1.118.
  65. R. A Mesa 1, C.-Y. Li, R. P Ketterling, G. S Schroeder, R. A Knudson, A. Tefferi Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-7. doi: 10.1182/blood-2004-07-2864. Epub 2004 Sep 23. DOI: 10.1182/blood-2004-07-2864
  66. J. Mascarenhas 1, S. Navada, A. Malone, A. Rodriguez, V. Najfeld, R. Hoffman Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010 Sep;34(9):1246-9. doi: 10.1016/j.leukres.2010.05.008. DOI: 10.1016/j.leukres.2010.05.008
  67. S. Thepot 1, R. Itzykson, V. Seegers, E. Raffoux, B. Quesnel, Y. Chait, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811.
  68. T. Badar 1, H. M Kantarjian 1, F. Ravandi 1, E. Jabbour 1, G. Borthakur 1, J. E Cortes Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep;39(9):950-6. doi: 10.1016/j.leukres.2015.06.001.
  69. S. O Ciurea 1, M. de Lima, S. Giralt, R. S., C. Bueso-Ramos, B. S Andersson, C. M Hosing, S. Verstovsek, R. E Champlin, U. Popat Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr;16(4):555-9. doi: 10.1016/j.bbmt.2009.12.004.
  70. C. Cherington 1, J. L Slack, J. Leis, R. H Adams, C. B Reeder, J. R Mikhael, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012 Sep;36(9):1147-51. doi: 10.1016/j.leukres.2012.04.021.
  71. Pedersen KM, Zangger G, Brochmann N, Grønfeldt BM, Zwisler AD, Hasselbalch HC, Tang LH. The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study. Eur J Cancer Care (Engl). 2018;27(5):e12865. doi: 10.1111/ecc.12865.
  72. Samuelson, Bethany T.; Vesely, Sara K.; Chai-Adisaksopha, Chatree; Scott, Bart L.; Crowther, Mark; Garcia, David The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagulation & Fibrinolysis. 2016; 27 (6): 648-652 doi: 10.1097/MBC.0000000000000446
  73. Шмаков Р.Г., Полушкина Е.С. Особенности репродуктивной функции у женщин с онкогематологическими заболеваниями. Современная онкология. 2008. 10(3).68-69

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*